Skip to main content
. Author manuscript; available in PMC: 2010 Apr 26.
Published in final edited form as: Int J Neuropsychopharmacol. 2009 May 13;12(10):1395–1408. doi: 10.1017/S146114570900042X

Fig. 4.

Fig. 4

Differential protein expression of NR2A and NR2B subunits in response to low and high doses of MK-801 treatment in PFC tissue. (a) Representative samples of Western blots showing the relative protein levels of NR2A and NR2B subunits to β-actin in response to treatment with MK-801 at 0.033 and 1.0 mg/kg, respectively. (b) Summary histogram showing the relative changes of NR2A and NR2B subunit proteins that were normalized to β-actin and then to the control with Tukey’s ANOVA test. It was clear that 0.33 mg/kg MK-801 treatment significantly increased protein expression of NR2A and NR2B subunits, whereas treatment with 1.0 mg/kg significantly decreased the expression of NR2A and NR2B subunits. The β-actin levels were stable without clear changes in both low- and high-dose treatments (* p<0.05).